• Molecular NamePentobarbital
  • SynonymPentabarbital; Pentabarbitone; Pentobarbital Sodium; Pentobarbitone; Pentobarbiturate; Pentobarbituric acid; Sodium Pentobarbital
  • Weight226.276
  • Drugbank_IDDB00312
  • ACS_NO76-74-4
  • Show 3D model
  • LogP (experiment)2.1
  • LogP (predicted, AB/LogP v2.0)2.02
  • pka8.0
  • LogD (pH=7, predicted)1.96
  • Solubility (experiment)0.679 mg/ml
  • LogS (predicted, ACD/Labs)(ph=7)-2.59
  • LogSw (predicted, AB/LogsW2.0)1.12
  • Sw (mg/ml) (predicted, ACD/Labs)0.53
  • No.of HBond Donors2
  • No.of HBond Acceptors5
  • No.of Rotatable Bonds4
  • TPSA75.27
  • StatusFDA approved
  • AdministrationOral, Intravenous, Intramuscular, Rectal; also Intraperitoneal & Intracardiac (for animal euthanasia)
  • PharmacologyPentobarbital's FDA approved human uses include treatment of seizures and preoperative (and other) sedation; it is also approved as a short-term hypnotic.
  • Absorption_value100.0
  • Absorption (description)N/A
  • Caco_2N/A
  • Bioavailability80.0
  • Protein binding51.0
  • Volume of distribution (VD)0.7 to 1 L/kg
  • Blood/Plasma Partitioning ratio (D_blood)N/A
  • MetabollsmPentobarbital undergoes first-pass metabolism in the liver and possibly the intestines.
  • Half life27 h
  • ExcretionRenal
  • Urinary ExcretionN/A
  • CleranceN/A
  • ToxicitySomnoless is the most common adverse event.
  • LD50 (rat)N/A
  • LD50 (mouse)LD50=117 (ip)